natgillin/translations-raw huggingface dataset:
An agonist is a chemical substance that binds to a specific receptor of a cell and triggers an activity by the cell.
Agonist je kemična snov, ki se veže na posebne receptorje vcelici in vnjej sproži odziv.
An agonist often mimics the action of endogenous or naturally occurring substances.)
Agonist pogosto posnema delovanje endogenih ali naravnih snovi.)
See the Drug profile ‘Synthetic cannabinoids and ‘Spice’’ on the EMCDDA website.)
Glej profil drog Sintetični kanabinoidi in „spice“ na spletišču Centra.)
Denmark, Germany, Estonia, Ireland, France, Latvia, Lithuania, Luxembourg, Austria, Poland, Romania, Sweden, United Kingdom.
Danska, Nemčija, Estonija, Irska, Francija, Latvija, Litva, Luksemburg, Avstrija, Poljska, Romunija, Švedska, Združeno kraljestvo.
Annual report 2010: the state of the drugs problem in Europe
Letno poročilo 2010: stanje na področju problematike drog v Evropi raziskavo, saj je samo 1% anketirancev poročal, da jo je uporabil več kot petkrat.
The latest Mixmag online survey, which targets club-goers in the United Kingdom, found that 56.6¢% of respondents reported having used ‘legal highs’.
V zadnji spletni raziskavi revije Mixmag, osredotočeni na obiskovalce klubov vZdruženem kraljestvu, je bilo ugotovljeno, da je 56,6% anketirancev poročalo ouporabi „dovoljenih drog“.
These included the herbal products ‘Spice’ and ‘Magic’, BZP party pills and other party pills, with last month prevalence of use of respectively 2.0¢%, 4.6¢% and 5.3¢%.
Med njimi so bili rastlinska proizvoda „spice“ in „magic“, „tabletke za zabavo“ BZP in druge „tabletke za zabavo“, katerih razširjenost uporabe vzadnjem mesecu je bila 2,0%, 4,6% oziroma 5,3%.
Respondents reported obtaining these drugs from friends (95¢%) or purchasing them on websites (92¢%), in shops (78¢%), from festival stalls (67¢%) or dealers (51¢%).
Anketiranci so poročali, da so te droge dobili od prijateljev (95%) ali so jih kupili na spletnih straneh (92%), vprodajalnah (78%), na stojnicah na festivalih (67%) ali od preprodajalcev (51%).
2010 survey identified only 21 shops offering ‘Spice’like products, compared with 55 in 2009.
Čeprav je bila študija iz leta 2010 obsežnejša, je bilo vnjej odkritih samo 21 prodajaln, ki ponujajo proizvode, podobne mešanici „spice“, vprimerjavi s55 prodajalnami leta 2009.
This year, two online shops offering ‘Spice’ were based in the United Kingdom, down from 23 last year.
Letos sta vZdruženem kraljestvu „spice“ ponujali dve spletni prodajalni, lani pa 23.
In the most recent snapshot, 15 shops claimed to have ‘Spice’ available, with eight of them revealing where they are located: three in the United States and one each in Spain, Poland, Portugal, Romania and the United Kingdom.
Vnajnovejšem pregledu je bilo ugotovljeno, da je 15 prodajaln trdilo, da imajo „spice“ na voljo, pri čemer jih je osem razkrilo svojo lokacijo: tri vZdruženih državah ter po ena vŠpaniji, na Poljskem, Portugalskem, vRomuniji in Združenem kraljestvu.
The remaining six online shops which offered ‘Spice’like products reported to be out of stock, and were possibly using the brand’s name to attract customers.
Preostalih šest spletnih prodajaln, ki so ponujale proizvode, podobne mešanici „spice“, je poročalo, da jih trenutno nimajo na zalogi, ime znamke pa so verjetno uporabljale za pritegnitev kupcev.
Follow-up on other substances
Spremljanje drugih snovi
Unlike illicit drugs, no large seizures of ‘Spice’like products were reported, and there is a lack of reports of criminality associated with the phenomenon.
V nasprotju sprepovedanimi drogami ni bilo poročil ovelikih zasegih proizvodov, podobnih mešanici „spice“, prav tako tudi ni poročil okriminaliteti, povezani stem pojavom.
This, combined with the limited knowledge about the chemistry and effects of the new compounds, creates a ‘grey zone’ around the monitoring of such products.
Zaradi tega in zaradi omejenega znanja okemiji in učinkih novih sestavin je spremljanje takih proizvodov „sivo področje“.
powders and tablets¢(159
Zbiranje in razlaganje podatkov ozasegih piperazinov postajata vedno bolj zapletena, saj gre za vrsto mešanic teh snovi, ki jih je mogoče najti vprahu in tabletah(159
Prevalence of ‘legal-highs’ use are also combined with other drugs such as amphetamine and MDMA.
Razširjenost uporabe „dovoljenih drog“ poleg tega pa se piperazini kombinirajo tudi zdrugimi drogami, na primer amfetaminom in MDMA.
In addition, forensic science laboratories do not always have the resources to identify all components of mixtures and in particular those that are not under control.
Forenzični laboratoriji tudi nimajo vedno možnosti za opredeljevanje vseh sestavin mešanic, predvsem tistih, ki niso nadzorovane.
The availability of BZP appears to have decreased following the 2008 Council decision to submit it to control measures throughout the European Union¢(160).
Evropski uniji začeli veljati nadzorni ukrepi(160).
Some
Vendar
The term ‘legal highs’ encompasses a wide range of products, from herbal mixtures to synthetic or ‘designer’ drugs and ‘party pills’, which are used in different ways (smoked, snorted, ingested).
Izraz „dovoljene droge“ zajema celo vrsto proizvodov od zeliščnih mešanic do sintetičnih ali „dizajnerskih“ drog in „tabletk za zabavo“, ki se uporabljajo različno (kadijo, vdihavajo, zaužijejo).
In addition, these products can be marketed as room odourisers, herbal incenses or bath salts, though they are intended for a different use.
Poleg tega se ti proizvodi lahko tržijo kot dišave, zeliščna kadila ali kopalne soli, čeprav so namenjeni za drugačno uporabo.
This diversity makes it difficult to collect and interpret prevalence data on ‘legal highs’.
Zaradi te raznovrstnosti je podatke o„dovoljenih drogah“ težko zbirati in pojasnjevati.
Member States, however, continue to report some large BZP seizures.
nekatere države članice še vedno poročajo ovelikih zasegih BZP.
Few recent surveys report prevalence data on the use of ‘legal highs’.
V nekaj novejših raziskavah se poroča opodatkih orazširjenosti uporabe „dovoljenih drog“.
A 2008 Polish study among 18-year-old students found that 3.5¢% had used ‘legal highs’ at least once, a figure comparable to the one for hallucinogenic mushrooms (3.6¢%).
Leta 2008 je bilo vpoljski raziskavi med osemnajstletnimi dijaki ugotovljeno, da jih je „dovoljene droge“ vsaj enkrat uporabilo 3,5%, kar je primerljivo spodatki za halucinogene gobe (3,6%).
The use of ‘legal highs’ during the last 12 months was reported by 2.6¢% of students¢(158).
O uporabi „dovoljenih drog“ vzadnjih 12 mesecih je poročalo 2,6% dijakov(158).
In 2009, mCPP still appeared to be the most widely available ‘new synthetic drug’¢(161) on the European ecstasy market, either alone or in combination with MDMA.
Leta 2009 je kazalo, da je mCPP še vedno najširše dostopna „nova sintetična droga“(161) na evropskem trgu zekstazijem.
The Dutch Drug Information Monitoring System also reported that the number of samples submitted by users for analysis had doubled compared to previous years, probably due to increased concerns regarding the adverse effects of piperazines.
Pojavljal se je samostojno ali vkombinaciji zMDMA.
The proportion of ecstasy tablets containing these substances may have fallen in the second half of 2009; in the United Kingdom, however, this
Podatki iz sistema za zgodnje opozarjanje, vključno sporočili uporabnikov na Nizozemskem ter zasegi na Danskem in vZdruženem kraljestvu, kažejo, da se je delež tablet ekstazija, ki so vsebovale mCPP (ali piperazine na splošno), vprvi polovici leta 2009 znatno povečal in morda presegel delež tablet ekstazija, ki vsebujejo MDMA.
A survey conducted among 1¢463 students aged between 15 and 18 years at schools providing general and vocational training in Frankfurt found that about 6¢% of respondents reported having used ‘Spice’ at least once, and 3¢% had used it during the last 30 days.
Po poročanju nizozemskega sistema za spremljanje informacij odrogah se je vprimerjavi sprejšnjimi leti podvojilo tudi število vzorcev, ki so jih
) 2008 CBOS survey, sample of 1¢400 adolescents of final grades at post middle schools; 15¢% of participants reported having used drugs in the last 12 months.)
) Raziskava CBOS iz leta2008 na vzrocu 1400 najstnikov vzadnjih letnikih srednjih šol; 15% sodelujočih je poročalo, da so droge uporabili vzadnjih 12 mesecih.) Na primer: BZP (1-benzilpiperazine), CPP (klorofenilpiperazin), TFMPP (1-(3-trifluorometilfenil)-piperazin) in DBZP (1,4-dibenzilpiperazin).
CPP has three positional isomers, which are often difficult to distinguish, of which mCPP (1-(3-chlorophenyl)piperazine) is the most prevalent.
CPP ima tri položajne izomere, ki jih je pogosto težko razlikovati, najpogostejši pa je mCPP(1-(3-klorofenil)piperazin). )
(160) Council Decision 2008/206/JHA of 3 March 2008 on defining 1-benzylpiperazine (BZP) as a new psychoactive substance which is to be made subject to control measures and criminal provisions (OJ L 63, 7.3.2008).(161) mCPP is not controlled internationally, but a number of European countries have implemented measures to control it in the last few years (Belgium,
Sklep Sveta 2008/206/PNZ zdne 3.marca2008 onadzornih ukrepih in kazenskih določbah za novo psihoaktivno snov 1-benzilpiperazin (BZP; UL L 63, 7.3.2008). ) mCPP se ne nadzoruje mednarodno, vendar je nekaj evropskih držav vzadnjih nekaj letih uvedlo ukrepe za nadzor nad njim (Belgija, Ciper, Danska, Nemčija, Grčija, Madžarska, Latvija, Litva, Malta, Romunija, Slovaška, Hrvaška, Turčija in Norveška).
Chapter 8: New drugs and emerging trends may have been partly offset by an increased availability of cathinone derivatives.
Poglavje 8: Nove droge in nastajajoči trendi uporabniki predložili vanalizo, najbrž zaradi vse večje zaskrbljenosti glede škodljivih učinkov piperazinov.
These changes reflect an increasingly complex ecstasy market, which can be explained by fluctuations in the availability of the MDMA precursor chemical PMK.
Te spremembe kažejo, da trg zekstazijem postaja vse bolj zapleten, kar je mogoče pojasniti znihanjem razpoložljivosti PMK, predhodne sestavine MDMA.
The Mixmag online survey targeting club-goers in the United Kingdom found last month prevalence of use of 1.7¢% for GHB and 1.6¢% for GBL, but 32.4¢% for ketamine.
Vspletni raziskavi revije Mixmag, ki se osredotoča na obiskovalce klubov vZdruženem kraljestvu, je bilo ugotovljeno, da razširjenost uporabe vzadnjem mesecu znaša 1,7% pri GHB in 1,6% pri GBL, pri ketaminu pa 32,4%.
A survey among club-goers in Amsterdam conducted in 2003 and 2008 (646 respondents) reported a slight increase in last month prevalence of GHB use from 4.2¢% to 4.7¢%.
Vraziskavi, opravljeni med obiskovalci klubov vAmsterdamu vletih 2003 in 2008 (646 anketirancev), so poročali orahlem povečanju razširjenosti uporabe GHB vzadnjem mesecu (s 4,2% na 4,7%).
In the Czech Republic, a 2008 survey among 363 club-goers found last month prevalence of use at 0.3¢% for GHB and 0.6¢%¢for ketamine.
VČeški republiki je bilo vraziskavi, opravljeni leta 2008 med 363 obiskovalci klubov, ugotovljeno, da razširjenost uporabe GHB vzadnjem mesecu znaša 0,3%, razširjenost uporabe ketamina pa 0,6%.
In London, a survey among 173 clubbers requesting medical assistance at a club medical room found that as many as two thirds requested it because of GHB/GBL use (Wood et al., 2009).
Raziskava med 173 obiskovalci londonskih klubov, ki so poiskali pomoč vklubskih sobah za zdravniško pomoč, je pokazala, da sta kar dve tretjini obiskovalcev pomoč poiskali zaradi uporabe GHB/GBL (Wood idr., 2009).
A survey regularly carried out among 15- to 16-year-old school students in Frankfurt found that the numbers offered GHB had increased from 1¢% in 2002 to 5¢% in 2008.
Vraziskavi, ki se redno opravlja med 15- in 16-letnimi dijaki vFrankfurtu, je bilo ugotovljeno, da se je število tistih, ki jim je bil ponujen GHB, povečalo z1% leta 2002 na 5% leta 2008.
GHB (gamma-hydroxybutyric acid) has been under international control since 2001, while ketamine, which is a medicinal product, may be controlled in Member States under either their legislation on drugs or on medicines.
GHB (gama hidroksibutirična kislina) je pod mednarodnim nadzorom od leta 2001, medtem ko lahko države članice ketamin, ki je zdravilo, nadzorujejo vskladu znjihovo zakonodajo odrogah ali zdravilih.
The use of gamma-butyrolactone (GBL), which is rapidly converted to GHB when ingested, has also recently raised concerns in Europe.
VEvropi je nedavno vzbudila skrb tudi uporaba gama-butirolaktona (GBL), ki se po zaužitju hitro pretvori vGHB.
GBL is considered a ‘non-scheduled drug precursor’ at EU level, and is included in the voluntary monitoring scheme for drug precursors.
GBL na ravni EU velja za „predhodno sestavino, ki ni uvrščena na sezname“, vključen pa je vprostovoljne sisteme za spremljanje predhodnih sestavin.
Some countries (Italy, Latvia, Austria, Sweden, United Kingdom, Norway) control it under their national drug legislation.
Nekatere države (Italija, Latvija, Avstrija, Švedska, Združeno kraljestvo in Norveška) ga nadzirajo znacionalno zakonodajo odrogah.
The prevalence of GHB and ketamine use in the general population is low, but it can be much higher in specific
Razširjenost uporabe GHB in ketamina med splošno populacijo je sicer majhna, vendar je lahko vnekaterih skupinah, okoljih in na geografskih območjih veliko večja.
The EMCDDA’s 2010 Internet snapshot found no online shops registered in the EU offering GHB, but GBL was found in four online shops.
Center vspletnem pregledu leta 2010 ni odkril nobene spletne prodajalne, registrirane vEU, ki bi ponujala GHB, vendar je bil vštirih spletnih prodajalnah odkrit GBL.
None of these, however, seemed to advertise GBL as a drug or implied that it could be used for its psychoactive properties.
Pri nobeni od teh prodajaln pa ni bilo videti, da bi GBL oglaševale kot drogo ali namigovale, da bi ga bilo mogoče uporabljati zaradi njegovih psihoaktivnih učinkov.
) Hyperlinks to online sources can be found in the PDF version of the annual report, available on the EMCDDA website (http://www.emcdda.europa. eu/publications/annual-report/2010).
) Hiperpovezave na spletne vire so vrazličici letnega poročila vformatu PDF, ki je na voljo na spletišču Centra (http://www.emcdda.europa.eu/publications/annual-report/2010).
EMCDDA (2008c), Drugs and vulnerable groups of young people, EMCDDA Selected issue, Publications Office of the European Union, Luxembourg.
EMCDDA (2009a), Letno poročilo 2009, stanje na področju problematike drog vEvropi, Urad za publikacije Evropske unije, Luxembourg.
EMCDDA (2009b), Internetbased drug treatment interventions: best practice and applications in EU Member States, EMCDDA Insights, Publications Office of the European Union, Luxembourg.
EMCDDA (2009d), Polydrug use: patterns and responses, izbrano vprašanje EMCDDA, Urad za publikacije Evropske unije, Luxembourg.
EMCDDA (2009c), Preventing later substance use disorders in at-risk children and adolescents, EMCDDA Thematic paper, Publications Office of the European Union, Luxembourg (available online).
EMCDDA (2009e), Drug offences, sentences and other outcomes, izbrano vprašanje EMCDDA, Urad za publikacije Evropske unije, Luxembourg.
EMCDDA (2009f), Understanding the ‘Spice’ phenomenon, EMCDDA Thematic paper, European Monitoring Centre for Drugs and Drug Addiction (available online).
EMCDDA (2009f), Understanding the „Spice“ phenomenon, tematski dokument EMCDDA, Evropski center za spremljanje drog in zasvojenosti zdrogami (na voljo na spletu).
ECDC and WHO Regional Office for Europe (2009), HIV/AIDS surveillance in Europe 2008, European Centre for Disease Prevention and Control, Stockholm.
ECDC in Regionalna pisarna za Evropo pri SZO (2009), HIV/AIDS surveillance in Europe 2008, Evropski center za preprečevanje in obvladovanje bolezni, Stockholm.
EMCDDA (2006), Hallucinogenic mushrooms, EMCDDA Thematic paper, European Monitoring Centre for Drugs and Drug Addiction (available online).
EMCDDA (2010c), Trends in injecting drug use in Europe, izbrano vprašanje EMCDDA, Urad za publikacije Evropske unije, Luxembourg.
EMCDDA (2010c), Trends in injecting drug use in Europe, EMCDDA Selected issue, Publications Office of the European Union, Luxembourg.
EMCDDA (2006), Hallucinogenic mushrooms, tematski dokument EMCDDA, Evropski center za spremljanje drog in zasvojenosti zdrogami (na voljo na spletu).
EMCDDA and Europol (2010), Cocaine: a European Union perspective in the global context, EMCDDA-Europol joint publications, Publications Office of the European Union, Luxembourg.
EMCDDA in Europol (2010), Cocaine: a European Union perspective in the global context, skupne publikacije EMCDDA in Europola, Urad za publikacije Evropske unije, Luxembourg.
Irish Prison Service (2009), Irish Prison Service annual report 2008 (available online).
Irish Prison Service (2009), Irish Prison Service annual report 2008 (na voljo na spletu).
NTA (2010), Powder cocaine: how the treatment system is responding to a growing problem (available online).
NTA (Nacionalna zdravstvena agencija za zlorabo snovi) (2006), Models of care for adult drug misusers: update (na voljo na spletu).
NOMS (National Offender Management Service) (2009), National Offender Management Service drug strategy 2008–2011, Ministry of Justice, London.
NOMS (Nacionalna služba za storilce kaznivih dejanj) (2009), National Offender Management Service drug strategy 2008–2011, ministrstvo za pravosodje, London.
NPIA (National Policing Improvement Agency) (2009), Digest, March (available online).
NPIA (Nacionalna agencija za boljši nadzor) (2009), Digest, marec (na voljo na spletu).
Low levels of negative health and social outcomes among non-treatment heroin users in Glasgow (Scotland)’, British Journal of Health Psychology 10, pp.¢33–48.
Sporer, K.A. (1999), „Acute heroin overdose“, Annals of Internal Medicine 130, str.585–90.
Wagner, F.A. and Anthony, J.C. (2002), ‘From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol’, Neuropsychopharmacology 26, pp.¢479–88.
UNODC (2010a), Afghanistan cannabis survey 2009, Urad za droge in kriminal pri Združenih narodih, Dunaj (na voljo na spletu).
How to obtain EU publications
Kako do publikacij Evropske Unije
The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction.
Center zbira, analizira in razširja dejanske, objektivne, zanesljive in primerljive informacije o drogah in zasvojenosti z njimi.
Indoing so, it provides its audiences with an evidencebased picture ofthedrug phenomenon at European level.
Tako svojemu občinstvu zagotavlja z dokazi podprto sliko pojava drog na evropski ravni.
The annual report presents the EMCDDA’s yearly overview of the drug phenomenon in the EU and is an essential reference book for those seeking the latest findings on drugs in Europe.
Letno poročilo predstavlja letni pregled pojava drog v Evropi s strani Centra in je najpomembnejši vir informacij za vse, ki iščejo najnovejše ugotovitve o drogah v Evropi.
Briefing of the European Monitoring Centre for Drugs and Drug Addiction www.emcdda.eu.int
Kratko poročilo Evropskega centra za spremljanje drog in odvisnosti od drog
Evaluation of the European Union’s strategy and actionplan (2000–2004)
Vrednotenje strategije in akcijskega načrta Evropske unije (2000–2004)
basis for a more well thought-out and lessheated debate.
Na ta način vrednotenje pripomore k manj gorečim razpravam z bolj pretehtanimi argumenti.
Evaluation is gradually coming to beaccepted as a necessary condition foraction in Europe, at least in terms ofstatements and intentions.
njenih učinkov in z njihovim doseganjem povezanih stroškov uvrsti med prednostne naloge.
Evaluation ofthe various kinds of intervention(prevention, treatment, etc.) and legalresponses has gained considerableground in recent years.
Vrednotenje postaja postopoma neizogiben pogoj za delovanje v Evropi.
While there is stillmuch progress to be made, there is nowa substantial body of literature thatscientifically documents the successes and failures of particular responses.
Ravno zaradi zapletenosti in resnosti vzrokov in posledic pojava drog je vrednotenje politike na tem področju še posebej uporabno.
Many of the strategies and plans drawnup by European Union (EU) Member
V zadnjih nekaj letih se je vrednotenje različnih ukrepov (preventiva, zdravljenje itd.) in pravnih odzivov občutno okrepilo.
Because the drug phenomenon, its causesand consequences are both complex andserious an evaluation of policy isparticularly useful in this field.
Nekatere države članice so tako začele z obsežnimi programi vrednotenja implementiranih politik, ki v mnogih primerih prispevajo k temu, da je država – pogosto prvič − odgovorna svojim državljanom glede tega, kaj počne, kako in kakšne rezultate dosega.
In permittinga reasoned value judgement of the effectsof public action, in other words, ajudgement based on a scientific basis,evaluation helps identify needs, improveselection, planning and implementation ofresponses and a more rational allocationof resources.
Ker daje utemeljeno, na trdnih znanstvenih temeljih osnovano vrednostno presojo, pomaga vrednotenje pri prepoznavanju potreb, boljši izbiri, načrtovanju in izvajanju ukrepov ter bolj racionalni razporeditvi sredstev.
It also avoids excessivehopes, which are sometimes undulyplaced on particular measures beforeknowing exactly what the effects will be.In this respect, evaluation can provide a
Čeprav bo potrebno storiti še veliko, je odslej na razpolago zadevna literatura, ki znanstveno utemeljuje uspehe in poraze določenih ukrepov.
States also state that evaluation of theimplementation of policy, its effects andthe costs incurred in achieving theseeffects (efficiency) should become apriority.
Številne strategije in načrti držav članic Evropske unije (EU) ravno tako predvidevajo, da se vrednotenje implementirane politike,
Some Member States havelaunched vast programmes for theevaluation of policies implemented, oftencontributing for the first time to theaccountability of the State to its citizens forwhat it does, how it does it and the resultsit achieves.
Prav tako odpravlja pretirane upe, ki jih včasih neupravičeno pripisujemo določenim ukrepom, katerih učinkov še sploh ne poznamo.
As such, evaluation is not onlyan activity which makes it possible toimprove the effectiveness and efficiency ofpublic action, but also a response to ademand for transparency which civilsociety has long and legitimatelydemanded in modern democracies.
Zato vrednotenje ni le dejavnost, ki prispeva k izboljšanju učinkovitosti in uspešnosti javnega delovanja, ampak prispeva tudi k večji transparentnosti, ki jo civilna družba v modernih demokracijah že dolgo in legitimno zahteva.
Evaluation: value judgement of a public intervention with reference to explicit criteria and standards.
Vrednotenje: vrednostna presoja javnega delovanja glede na določene kriterije in standarde.
The judgement primarily concerns the needs which have to be met by the intervention, and the effects produced by it.(MEANS, 1999).
Presoja v prvi vrsti upošteva potrebe samega delovanja in učinkov, ki mu sledijo. (MEANS, 1999).
2.Evaluation and the European Union drug strategyand action plan
Zato bi morala med obema dokumentoma obstajati povezanost in skladnost, kar pa v tem primeru ne velja vedno.
Moreover, some of the stated objectivesremain very general, and there are nocriteria for measuring the degree ofsuccess or failure of the strategy andaction plan in achieving these objectives.
2. ocena, do katere stopnje se implementacija akcijskega načrta ujema s cilji strategije; 3. vrednotenje učinkov na pojav drog.
The EU strategy and action plan (2000–2004) are no exception to this trend: forthe first time, evaluation is laid down as apriority objective in these two documents.While this is a legitimate objective thatreflects a very widespread practice inmany other EU actions, in this case thetask is far from easy.
Strategija in akcijski načrt EU (2000–2004) sledita tendenci: v obeh dokumentih je vrednotenje prvič zastavljeno kot prednostni cilj.